Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6120948 | Journal of Clinical Virology | 2012 | 5 Pages |
Abstract
In all gB groups (individual gB genotype infections and mixed genotype infections) there was a biphasic decline in viral load after therapy. The first phase half life (days 0-3) was â¤1 day and was followed over the next 18 days by a slower second phase decline with half lives ranging from 3.4 to 4.4 days. The 1st phase rapid decline in viral load was dependent upon gB genotype whereas the ultimate viral load reduction at day 21 was relatively insensitive to gB genotype. A strong correlation between 1st phase decline and extent of viral load reduction at day 21 was observed (r = 0.37; p = 0.002). These data imply that early reductions in HCMV load after therapy may be useful in predicting the duration of drug therapy needed to control HCMV replication.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Vincent C. Emery, Oriol Manuel, Anders Asberg, Xiaoli Pang, Deepali Kumar, Anders Hartmann, Jutta K. Preiksaitis, Mark D. Pescovitz, Halvor Rollag, Alan G. Jardine, Christoph G. Gahlemann, Atul Humar,